The most common treatment-related grade @-@ adverse event in the pembrolizumab groups was fatigue ( two -LSB- @ % -RSB- of @ patients in the @ mg/kg group and one -LSB- < @ % -RSB- of @ patients in the @ mg/kg group , compared with eight -LSB- @ % -RSB- of @ in the chemotherapy group ) .